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Purpose: To develop a sensitive and rapid reverse phase high performance liquid chromatography 
(HPLC) method for the measurement of the levels of zidovudine (ZVD) and nevirapine (NVP) in human 
plasma.  
Methods: Standard stock solutions for HPLC analysis were prepared by dissolving ZVD and NVP in 
methanol. In the HPLC measurement, sample detection was carried out at 246 nm using an ultraviolet 
(UV)-photo diode array (PDA) detector. Plasma sample pretreatment consisted of protein precipitation 
extraction with methanol. The compounds were separated using a mobile phase consisting of a pH 3.0 
solution (obtained by adjusting the pH of water with orthophosphoric acid): acetonitrile (73:27 v/v) on a 
Phenomenex LUNA C18, column (250×4.6 mm i.d., 5µm) at a flow rate of 0.9 mL min
-1
. The total run 





 for ZVD and NVP, respectively.    
Results: The lowest limits of quantification (LLOQ) and of detection (LOD) were 300 and 63 ng mL
-1
 for 
ZVD and 200 and 17 ng mL
-1
 for NVP, respectively. The method was found to be accurate, with 
accuracy ranging from -10.92 to +9.57 % and precise, with intra-day, inter-day as well as analyst to 
analyst precision of 0.68 to 9.38 %. Extraction recoveries of the drugs from plasma were 91.39, 95.01, 
89.51 % for ZVD and 90.93, 93.26, 92.13 % for NVP, for LQC (low quality control), MQC (medium 
quality control) and HQC (high quality control) samples, respectively. Stability data revealed that the 
drugs were stable in plasma under various test conditions. 
Conclusion: This assay can be suitably used for the determination of zidovudine (ZVD) and nevirapine 
(NVP) in human plasma and should be useful in HIV clinical trials and clinical therapeutic drug 
monitoring (TDM) programs. It would also be potentially useful in the determination of pharmacokinetic 
profiles and in bioequivalence studies in HIV research. 
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INTRODUCTION 
 
Major advances have been accomplished in 
recent years in the treatment of patients 
infected with human immunodeficiency virus-
type 1 (HIV-1). However, many patients 
experience treatment failure within one year 
after initiation of antiretroviral therapy
1
.  
Combination therapy has now become the 




need for such a therapy has arisen due to the 
development of resistance by human 
immunodeficiency virus (HIV), to single anti-
HIV drugs and also in order to minimize the 
dose-dependent side effects produced by 
these drugs
3
. Many drugs have been tested 
for their activity against HIV-1. Nevirapine 
(NVP), a  representative of a new class of 
antiretroviral drugs - the non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) - 
i.e., 11-cyclopropyl-5,11-dihydro-4-meth yl-
6H-dipyrido- [3,2-b:2,3 e] [1,4] diazepin-6-one, 
and zidovudine (ZVD), i.e., 3-azido- 3-
deoxythymidine, are synthetic nucleoside 
analogues used for the treatment of HIV 
infections (Fig. 1).  
 
Several multi-drug high-performance liquid 
chromatography (HPLC) assays that measure 
a number of NNRTIs have been described in 
the literature in recent years. Numerous 
analytical methods, such as HPLC with UV 
detection, mass spectrometry detection and 
immunoassay, have been reported for ZVD 
and NVP but they either use a gradient 
method for separation or a complicated liquid-
liquid extraction method for preparation of 
plasma samples and also often involve 
complicated chromatography techniques. In 






 have been described. A few 
methods to estimate zidovudine and 
nevirapine simultaneously have also been 
reported
12–17
. Some of these methods used 
liquid–liquid
12-14
 and solid phase extraction 
procedure for the extraction of the drugs from 
plasma
15–17
. This could increase the time and 
cost of the assay. However, a combination of 
several characteristics makes this assay a 
unique and a useful analytical tool for 
quantification of these drugs.  
 
The objective of this work was to devise a 
simultaneous technique for the quantitative 
evaluation of zidovudine (ZVD) and nevirapine 
(NVP) in human plasma which involves rapid 
protein precipitation extraction and based on 
simple chromatographic conditions with 
detection at a single wavelength (246 nm) 
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EXPERIMENTAL 
 
Reagents and chemicals 
 
Zidovudine and nevirapine were kindly 
provided by Ranbaxy Laboratories Ltd, 
Dewas, (M.P.), India. Methanol and 
acetonitrile were of HPLC grade and 
purchased from Merck Ltd, New Delhi, India. 
Water used was of HPLC grade water (Mili Q 
Water) was purchased from Ranbaxy 
Laboratories Ltd, (New Delhi, India). Human 
plasma was obtained from Blood Bank 
Department, Bhopal Memorial Hospital & 
Research Centre, Bhopal, (M.P.), India. All 
other chemicals were of analytical grade and 




The HPLC system (Shimadzu, Japan) 
consisted of a LC-10AT VP pump, a SPD-10A 
VP, PDA detector, a Phenomenex, Luna C18 
(250mmX4.6mm, 5µm) column, a 
Phenomenex, HPLC guard cartridge system 




The chromatographic analysis was performed 
at ambient temperature on a Phenomenex 
LUNA analytical column with a mobile phase 
composed of water (pH 3.0, adjusted with 
orthophosphoric acid): acetonitrile (73:27, v/v) 
and was isocratically eluted at a flow rate of 
0.9 mL min
-1
. A small sample volume of 20 µL 
was used for each sample run, being injected 
into the HPLC system. The chromatogram 
was monitored with UV detection at a 
wavelength of 246 nm. 
 
Preparation of the calibration standards, 
mixed standard and quality control (QC) 
samples  
 
Standard stock solutions were prepared by 
dissolving 60 mg of ZVD and 40 mg of NVP in  
100 mL of methanol to obtain final 
concentrations of 600 and 400 µg mL
-1
 for 
ZDV and NVP, respectively (stock-A). From 
this stock, 1 mL was taken and diluted to 10 
mL with methanol to give 60 µg mL
-1
 of ZVD 
and 40 µg mL
-1
 of NVP standard solutions, 
respectively (Stock-B). Aliquots of stock-B 
were further diluted to obtain different 
concentrations: 300, 600, 1800, 3000, 4800, 
6000, 7800, 9600 ng mL
-1
 for ZDV and 200, 
400, 1200, 2000, 3200, 4000, 5200, 6400 ng 
mL
-1
 for NVP. To prepare standard spike 
plasma stock solutions, 1 mL was taken from 
stock-A, and diluted to 10mL with blank 
plasma to give 60 µg mL
-1
 of ZVD and 40 µg 
mL
-1
 of NVP (stock-C). From the working 
standard solution stock-C, different 
concentrations were prepared by taking 0.1, 
0.2, 0.4, 0.6, 0.8, 1.2, 1.6, and 1.8 mL, and 
then the volume was made up, in each case, 
to 2 mL with blank plasma. For all the 
concentrations, 8 mL of precipitating agent 
(methanol) was added to obtain the final 
concentrations of 300, 600, 1800, 3000, 4800, 
6000, 7800, 9600 ng mL
-1
 for ZVD and 200, 
400, 1200 2000, 3200, 4000, 5200, 6400  ng 
mL
-1
 for NVP.  
 
QC samples at three different levels of HQC 
(high quality control, 6000/4000 ng mL
-1
), 
MQC (medium quality control, 3000/2000 ng 
mL
-1
), LQC (low quality control, 600/400 ng 
mL
-1
) and LLOQ (lowest limit of quantitation, 
300/200 ng mL
-1
) for ZVD and NVP, 
respectively, were selected to perform 
different validation parameters. 
 
Sample pretreatment and extraction 
procedure 
 
Drugs were extracted from plasma samples 
using a protein precipitation technique. 
Methanol was selected as the precipitating 
agent. Each plasma sample gave satisfactory 
values for recovery with a single extraction. 
The satisfactory result was obtained when 1:4 
ratios of plasma and methanol were mixed 
thoroughly, vortexed at room temperature and 
centrifuged at 12000 rpm for 10 min at 4°C. 
The clear supernatant liquid was decanted, 
filtered through a 0.45 µm syringe filter and 
injected (20 µL) into HPLC system. 
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Limit of detection (LOD) and lowest limit of 
quantification (LLOQ) 
 
The limit of detection (LOD) was defined as 
the concentration that yields a signal-to-noise 
ratio of 3. The lowest limit of quantification 
(LLOQ) was calculated to be the lowest 
analyte concentration that could be measured 
with a signal-to-noise ratio of 10. To determine 
LLOQ and LOD, plasma samples were spiked 
with decreasing concentrations of the analytes 
and analyzed. The LLOQ and LOD were 
observed 300 and 63 ng mL
-1
 for ZVD while 





Linearity of method 
 
Calibration plots for the analytes in plasma 
were prepared by spiking drug-free plasma 
with standard stock solutions to yield 
concentrations of 300-9600 ng mL
-1
 for ZVD 
and 200-6400 ng mL
-1
 for NVP. The solutions 
were injected in replicates (n = 5) into the 
HPLC column while keeping the injection 
volume constant (20 µL). Calibration curves 
were constructed by using ratios of the 
observed analyte peak area versus 
concentration of analyte. Intercept, slope and 
correlation coefficient (r
2
) were determined by 
linear regression data analysis, which were 
then used to calculate the analyte 
concentration in each sample. 
 
Precision and accuracy of method 
 
The inter-day, intra-day, analyst to analyst 
precision and accuracy of the assay were 
determined by assaying three QC samples 
and LLOQ in replicates (n = 5) for each drug. 
Precision was reported as percent relative 
standard deviation (% RSD) and accuracy 
was as % nominal concentration and % bias. 
 
Recovery of zidovudine and nevirapine 
from plasma 
 
Recovery from plasma was determined for QC 
samples of each drug by comparing the peak 
area of each analyte after extraction with the 
respective non-extracted standard solutions at 
the same concentration. The percentage of 
the drug recovered from the plasma samples 
was determined by comparing the peak height 
ratio after extraction with those of unextracted 
sample containing same concentrations of the 




Selectivity is the ability of an analytical method 
to differentiate and quantify the analyte in the 
presence of other components in the sample. 
To evaluate the selectivity of the assay, blank 
samples of the appropriate biological matrix 
(plasma) were prepared from six different 
sources. 
 
Stability of method 
 
Stability of drugs in biological fluids is a 
function of the sample storage conditions, 
chemical properties of the drug, matrix and 
the container system
18
. Blank samples were 
spiked with appropriate aliquots of diluted 
ZVD and NVP stock solutions to prepare LQC 
and HQC samples. The stability of drugs was 
evaluated under conditions likely to be 
encountered during actual sample handling 
and analysis. These samples were kept to 
evaluate different stability parameters such as 
stock solution stability (SSS, 6 h at room 
temperature), bench top stability (BTS, 12 h at 
room temperature), post processing stability 
(PPS, over the maximum time, i.e., from the 
completion of sample work-up to the 
completion of data collection), freeze and 
thaw stability (FTS, subjected to three freeze–
thaw cycles of -20 
0
C during 24 h) and long-
term storage stability (LTS, subjected to 
freeze storage at -20 
0
C during the entire 
period covered by the bioanalytical study, i.e., 
from the first day of sample preparation to the 
last day of sample analysis). For each 
concentration and storage conditions three 
replicates were analyzed. The concentration 
of ZVD and NVP after each storage period 
was related to the initial concentration as 
determined for the samples that were freshly 
prepared and processed immediately. 
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RESULTS  
 
At the chromatographic conditions selected for 
this method, the retention time for blank 
plasma (Fig. 2) and extracted peaks of ZVD 
and NVP (Fig. 3) were 2.7 ± 0.3 min, 5.2 ± 0.3 
min and 9.5 ± 0.3 min, respectively. The 
correlation coefficients for the linearity of the 
present method were 0.9997 and 0.9995 for 
ZVD and NVP respectively. The lowest limit of 
quantification and limit of detection were found 
to be 300 and 63.0 ng mL
-1
 and 200 and 17.0 
ng mL
-1
 for ZVD and NVP, respectively. The 
recovery of the extraction procedure for ZVD 
was 95.39 %, 94.01 % and 89.51 % while for 
NVP, it was 94.93 %, 93.26 % and 92.13 % 
for HQC, MQC & LQC, respectively (Table 1). 
The accuracy (% nominal conc.) for HQC, 
MQC, LQC and LLOQ, samples were found to 
be in the range 93.42 to 109.79 and 89.04 to 
105.15 for ZVD and NVP, respectively. The 
accuracy data are shown in the Table 1 and 
were well within the acceptance limit. The 
precision data for HQC, MQC, LQC & LLOQ 
samples were analyzed in replicates (n = 5) 
(Table 1). For intra-day, it was 1.47 to 8.59 % 
and 2.42 to 7.15 % for ZVD and NVP, 
respectively.  For inter-day, the range was 
1.93 to 9.38 % and 1.35 to 8.98 %, for ZVD 
and NVP, respectively, while for analyst to 
analyst precision, it was in the range 0.68 to 




Table 1: Accuracy, precision and mean recovery data for the developed method 
       
           QC                  Accuracy                             Precision                           Mean                               
           Samples                                                                                                              Recovery (%)                                 
                                      % N.C. 
a
        % Bias      Intra day     Inter day       A-to-A 
b
                        
ZVDc    LLOQ 
d         
       104.38            4.38            8.59           9.38               4.50                       -                                    
            LQC 
e
               97.70            -2.30            2.34           7.03               5.94                   91.39                                       
            MQC 
f                 
109.79             9.79            5.51           4.37               2.62                   95.01                                        
            HQC 
g
                 93.42            -6.58           1.47           1.93               0.68                   89.51 
                                            
NVP
h
   LLOQ                 89.08             -10.92         6.26           5.92              5.50                       - 
            LQC                    98.44             -1.56          7.15            8.98              3.72                    90.93                            
            MQC                106.15               6.15          2.42            2.67              6.82                    93.26                                
            HQC                100.80               0.80          4.13            1.35              1.79                    92.13                              
 
a  
% Nominal concentration; 
b




 lowest limit of quantitation; 
e
 low quality control; 
f
 medium 
quality control;  
g





Table 2: Stability of the developed method at various conditions 
 
Stability                           Zidovudine                                      Nevirapine 
conditions           LQC                           HQC                                LQC                     HQC 
                    
                 % N.C.
a
       % C.
b
       % N.C.      % C.           % N.C.       % C.          % N.C.          % C.      
SSS 
c
         92.68           4.94         98.45       -1.13            103.73      2.83            92.69          -5.31 
BTS 
d
         95.51          -2.23         88.60       -7.52              97.15      6.25            94.92          -1.63  
PPS 
e
      103.53            5.21         99.35       -3.23              91.59     -9.69            99.40           1.11            
FTS 
f
         96.58            3.51         91.96       -5.43              99.57      8.95           104.10          5.49          
LTS 
g
       107.25           8.28       102.74         6.26           109.50     11.97           105.60         -0.51          
 
a  




 stock solution stability;  
d
 bench top stability;  
e
 post processing stability;  
f
 
freeze & thaw stability;  
g
 long term stability 
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The stability test results (% change) for ZVD 
at 6000 and 600 ng mL
-1
 were [(4.94 and -
1.13 for SSS), (-2.23 and -7.52 for BTS), (5.21 
and -3.23 for PPS), (3.51 and -5.43 for FTS), 
(8.28 and 6.26 for LTS)] and for NVP at 4000 
and 400 ng mL
-1
, they were [(2.83 and -5.31 
for SSS), (6.25 and -1.63 for BTS), (-9.69 and 
1.11 for PPS), (8.95 and 5.49 for FTS), (11.97 
and -0.51 for LTS)] as illustrated in Table 2. 
The result of % change demonstrates that 
stability testing of ZVD & NVP were within the 





The present study describes a sensitive, 
accurate, and reproducible HPLC method for 
the determination of ZVD and NVP in human 
plasma. Here, we used a simple protein 
precipitation with a small quantity of plasma 
and precipitating agent, which considerably 
reduced the sample processing time. There is 
no need to use an internal standard as 
recovery of the method was found to be more 
than 90 %. The mobile phase used in this 
study was economical, simple and the assay 
was entirely isocratic involving only two stable 
solvent components, water and acetonitrile; 
thus the chances of column damage were 
negligible, which gives the column a longer life 
span. 
 
In order to obtain the most suitable 
wavelength for the detection of ZVD and NVP, 
a UV spectrum was obtained. The UV 
spectrum revealed that maximum absorbance 
peaks were 266 nm for ZVD and 283 nm for 
NVP but the selected wavelength was 246 
nm. Although this was not the maximum 
absorption wavelength for either of the drugs, 
it, nevertheless, provided good signal to noise 
ratio and selectivity. 
 
The retention time for ZVD and NVP were 5.2 
± 0.30 min & 9.5 ± 0.30 min, respectively. 
Blank plasma samples did not give any peak 
at the retention time of these drugs.  The 
LLOQ value, 300 and 200 ng mL
-1
 for ZVD 
and NVP, respectively, allowed us to avoid the 
use of expensive and sensitive detectors. The 
calibration curve derived from eight different 
concentration points ranging from 300 to 9600 
ng mL
-1
 for ZVD and 200 to 6400 ng mL
-1
 for 
NVP, showed a linear relationship between 
area under curve (AUC) and concentration. 
The mean extraction recovery of 92.97 % for 
ZVD and 93.44 % for NVP is satisfactory 
since no comprehensive method of extraction 
was used. The accuracy and precision data 
are well under the acceptance limit (± 20% for 
LLOQ, and ± 15% for LQC, MQC and HQC). 
The stability data of analytes show that the 
drugs are stable in plasma under the varying 




A simple, sensitive, isocratic, reverse phase 
HPLC-UV assay was developed and validated  
for the simultaneous analysis of zidovudine 
and nevirapine in human plasma. The small 
volume plasma sample preparation involved 
rapid protein precipitation extraction, making it 
widely applicable for HIV clinical therapeutic 
drug monitoring programs. The results of this 
study indicates that the method would be 
applicable to toxicokinetic, pharmacokinetic, 
bioavailability, and bioequivalence 
studies.This HPLC method should also be 
useful for analyzing plasma concentrations of 
the drugs evaluated as well as 
pharmacokinetic parameters in HIV-infected 
patients for the purpose of evaluating clinical 
pharmacology and clinical therapeutic drug 
monitoring (TDM) programs for these drugs in 
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